Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2705-2711

  Kummar, Shivaani ^a   Kinders, Robert ^a   Gutierrez, Martin E ^a   Rubinstein, Larry ^a   Parchment, Ralph E ^a   Phillips, Lawrence R ^a   Ji, Uping ^a   Monks, Anne ^a   Low, Jennifer A ^a   Chen, Alice ^a   Murgo, Anthony J ^a   Collins, Jerry ^a   Steinberg, Seth M ^a   Eliopoulos, Helen ^a   Giranda, Vincent L ^a   Gordon, Gary ^a   Helman, Lee ^a   Wiltrout, Robert ^a   Tomaszewski, Joseph E ^a   Doroshow, James H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); 2 ((R) 2 METHYLPYRROLIDIN 2 YL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CARCINOID; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; DNA DAMAGE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SAMPLE SIZE; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR BIOPSY; BIOAVAILABILITY; BIOPSY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEASIBILITY STUDY; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BIOPSY; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 66849106010     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.7681     Document Type: Article

References (26)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715, 2004
2. US Food and Drug Administration: Guidance for Industry, Investigators, and Reviewers. Rockville, MD, US Food and Drug Administration, 2006. http://www.fda.gov/cder/guidance/7086fnl.pdf
3. Kummar S, Kinders R, Rubinstein L, et al: Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 7:131-139, 2007
4. Amé JC, Spenlehauer C, de Murcia G: The PARP superfamily. Bioessays 26:882-893, 2004
5. Tulin A, Chinenov Y, Spradling A: Regulation of chromatin structure and gene activity by poly (ADP-ribose) polymerases. Curr Top Dev Biol 56:55-83, 2003
6. Schreiber V, Dantzer F, Amé JC, et al: poly (ADP-ribose): Novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528, 2006
7. Tomoda T, Kurashige T, Moriki T, et al: Enhanced expression of poly (ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 37: 223-227, 1991
8. Shiobara M, Miyazaki M, Ito H, et al: Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16:338-344, 2001
9. Masutani M, Nozaki T, Nakamoto K, et al: The response of Parp knockout mice against DNA damaging agents. Mutat Res 462:159-166, 2000
10. de Murcia JM, Niedergang C, Trucco C, et al: Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 94:7303-7307, 1997
11. Alderson T: New targets for cancer chemotherapy-poly (ADP-ribosylation) processing and polyisoprene metabolism. Biol Rev Camb Philos Soc 65:623-641, 1990
12. Jagtap P, Szabó C: poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440, 2005
13. Tentori L, Graziani G: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52:25-33, 2005
14. Plummer ER: Inhibition of poly (ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 6:364-368, 2006
15. Donawho CK, Luo Y, Luo Y, et al: ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728-2737, 2007
16. Albert JM, Cao C, Kim KW, et al: Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13: 3033-3042, 2007
17. Ratnam K, Low JA: Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 13:1383-1388, 2007
18. Kinders RJ, Hollingshead M, Khin S, et al: Preclinical modeling of a phase 0 clinical trial: Qualification of a pharmacodynamic assay of poly (ADPribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 14:6877-6885, 2008
19. Phillips LR, Hill KD, Majerova E, et al: Liquid chromatographic determination of NSC 737664 (ABT-888: an inhibitor of poly (ADP-ribose) polymerase (PARP)) in plasma and urine in a phase 0 clinical trial. J Liq Chromatogr Relat Technol 32:261-272, 2009
20. Murgo AJ, Kummar S, Rubinstein L, et al: Designing phase 0 cancer clinical trials. Clin Cancer Res 14:3675-3682, 2008
21. Ji J, Redon C, Pommier Y, et al: Polyadeninosinediphosphate-ribose polymerase inhibitors as sensitizers for therapeutic treatments in human tumor and blood mononuclear cells. J Clin Oncol 25:613s, 2007 (suppl; abstr 14024)
22. National Center for Biotechnology Information Entrez SNP Database, dbSNP Build 129. http:// www.ncbi.nlm.nih.gov/sites/entrez?db=snp
23. Kinders R, Parchment RE, Ji J, et al: Phase 0 clinical trials in cancer drug development: From FDA guidance to clinical practice. Mol Interv 7:325-334, 2007
24. Dowlati A, Haaga J, Remick SC, et al: Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7:2971-2976, 2001
25. Helft PR, Daugherty CK: Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol 24:4793-4795, 2006
26. Gutierrez M, Collyar D: Patient perspectives on phase 0 clinical trials. Clin Cancer Res 14:3689-3691, 2008